NUCLIDIUM
Nuclidium’s vision is to address the unmet need to detect and stage cancer more accurately so that treatment options for cancer patients and their long-term survival can be significantly improved.
NUCLIDIUM
Social Links:
Industry:
Health Care Medical
Founded:
2017-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.nuclidium.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
2.4 M CHF
Investors List
European Innovation Council
European Innovation Council investment in Grant - Nuclidium
Official Site Inspections
http://www.nuclidium.com
- Host name: sh20024.ispgateway.de
- IP address: 92.205.54.255
- Location: Germany
- Latitude: 51.4476
- Longitude: 7.0122
- Timezone: Europe/Berlin
More informations about "Nuclidium"
NUCLIDIUM - Crunchbase Company Profile & Funding
NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. See details»
Nuclidium - Products, Competitors, Financials, Employees, …
Nuclidium is a company focused on developing best-in-class copper-based radiopharmaceuticals for the precision oncology industry. Its main offerings include a proprietary CuTrace platform … See details»
Nuclidium - 2025 Company Profile & Team - Tracxn
2 days ago Nuclidium is a series B company based in Basel (Switzerland), founded in 2017 by Leila Jaafar. It operates as a Developer of radiopharmaceuticals for the treatment of cancer. … See details»
Nuclidium 2025 Company Profile: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for Nuclidium. Use the PitchBook Platform to explore the full profile. See details»
NUCLIDIUM - VentureRadar
NUCLIDIUM Location: Switzerland Founded in 2017 Develops personalized cancer therapies using copper radiometals and targeted molecules for improved safety, efficacy, and economic … See details»
Swiss BioTech platform NUCLIDIUM raises €84 million …
5 days ago Basel-based NUCLIDIUM, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced the successful closing of its Series B financing round, raising €84 … See details»
Nuclidium company information, funding & investors | Dealroom.co
Mar 1, 2017 Nuclidium, setting a new standard in the precision oncology landscape by developing best-in-class copper-based radiopharmaceuticals that enable the highest accuracy … See details»
About Us – Nuclidium
NUCLIDIUM’s vision is to address the unmet need in cancer medicine by providing personalised treatment options for cancer patients at every stage of their disease to improve long-term … See details»
NUCLIDIUM Closes CHF 79 Million (EUR 84 Million) Series B
4 days ago NUCLIDIUM AG is a clinical-stage biotechnology company pioneering the development of next-generation copper-based radiopharmaceuticals for the diagnosis and … See details»
Nuclidium fuels next radiopharma wave - european …
4 days ago Nuclidium fuels next radiopharma wave Basel-based NUCLIDIUM AG has successfully closed a Series B financing round of CHF 79 million (EUR 84 million) to advance … See details»
NUCLIDIUM Closes CHF 79 Million (EUR 84 Million) Series B …
4 days ago Proceeds will fund further clinical development of the company’s true theranostic pipeline and expansion of the global production and manufacturing network for copper-based … See details»
PharmaLogic - Radiopharmacy
NUCLIDIUM's copper-based platform has the ability to bring us closer to this vision, and I look forward to working with this highly skilled team to advance radiopharmaceutical products … See details»
NUCLIDIUM Closes CHF 79 Million (EUR 84 Million) Series B …
5 days ago Basel, Switzerland / Munich, Germany, July 10, 2025 – NUCLIDIUM, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, … See details»
Nuclidium Raises $99M in Series B Financing
4 days ago NEW YORK – Radiopharmaceutical company Nuclidium has raised $99 million in Series B financing to advance its copper-61 and copper-67 theranostics, the firm announced … See details»
NUCLIDIUM and PharmaLogic Form Strategic Partnership for …
May 15, 2023 NUCLIDIUM’s easy-to-apply proprietary production process allows for fast and easy integration into an installed cyclotron and existing supply networks for PET-FDG, making … See details»
News – Nuclidium
Jun 17, 2024 The European Innovation Council (EIC) has awarded Nuclidium with its Accelerator grant of €2,5 million to develop novel, broadly available Copper-based PET tracers … See details»
Nuclidium Nets $99M Series B for Copper-Based Radiopharma …
4 days ago Nuclidium’s radiopharmaceutical platform is unique in its use of copper-based payloads, which the biotech claims can deliver higher doses while also being safer. See details»
Nuclidium and Actiphera raise big in radiopharma
5 days ago Take a closer look at the radiopharma new wave as Nuclidium and Actithera raise big to develop their platforms. See details»
NUCLIDIUM and PharmaLogic Form Strategic Partnership for …
May 15, 2023 NUCLIDIUM and PharmaLogic Form Strategic Partnership for Sustainable Development of Novel Copper-based Theranostics to Diagnose and Treat Solid Tumours … See details»
Technology – Nuclidium
Our proprietary CuTraceâ„¢ platform utilises the unique properties of copper radionuclides in combination with tumour-specific molecules to create therapeutic and diagnostic pairs with an … See details»